LivaNova PLC LIVN
At closeNov 5, 2026, 4:39 PM EST
After hours · Nov 5, 4:39 PM ET
- YTD
- +48.12%
- 1 year
- +79.37%
- Market cap
- 5.01B
- Revenue (ttm)
- 1.47B
- Profit margin
- 12.81%
- EPS (ttm)
- 3.38
- Shares out
- 54.93M
- P/E ratio
- 26.96
- Forward P/E
- 20.11
- YTD return
- +48.12%
- 1-year return
- +79.37%
- Volume
- 1.24M
- Avg volume
- 670.07K
- Open
- 93.77
- Previous close
- 94.19
- Day's range
- 88.81 – 94.22
- 52-week range
- 48.82 – 99.38
- Beta
- 0.92
- Analysts
- Buy
- Price target
- 90.55 (-0.7%)
- Earnings date
- Feb 24, 2027
5D +10.85 (+13.51%)
Key statistics
- Enterprise value
- 4.24B
- PEG ratio
- 0.93
- Price / sales
- 3.52
- Price / book
- 3.91
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 10.80%
- Free cash flow
- 59.87M
- Total cash
- 516.62M
- Total debt
- 351.95M
- Return on equity
- 15.40%
- Short % of float
- 12.92%
- 50-day average
- 78.56
- 200-day average
- 73.07
Analyst view
Consensus: buy
- Target (low)
- 75.00
- Target (mean)
- 90.55
- Target (high)
- 105.00
- Strong buy3
- Buy6
- Hold2
- Sell0
- Strong sell0
Next earnings
Feb 24, 2027
Expected Feb 24, 2027. Consensus EPS estimate 1.06.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 24, 2027 | Dec 30, 2026 | 1.07 | — | — | — |
| Nov 4, 2026 | Sep 30, 2026 | 1.06 | 1.23 | +0.17 | +16.04% |
| Aug 5, 2026 | Jun 30, 2026 | 1.09 | 1.26 | +0.17 | +15.60% |
| May 6, 2026 | Mar 31, 2026 | 0.85 | 0.98 | +0.13 | +15.29% |
| Feb 25, 2026 | Dec 31, 2025 | 0.80 | 0.86 | +0.06 | +7.50% |
| Nov 5, 2025 | Sep 30, 2025 | 0.919 | 1.11 | +0.19 | +20.78% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 4, 2026 | Needham | main | Buy | Buy |
| Oct 7, 2026 | Barclays | init | — | Overweight |
| Sep 2, 2026 | Piper Sandler | reit | Overweight | Overweight |
| Aug 5, 2026 | Needham | main | Buy | Buy |
| Jul 15, 2026 | Mizuho | main | Outperform | Outperform |
| Jul 1, 2026 | Freedom Capital Markets | init | — | Hold |
About LivaNova PLC
LivaNova PLC, a medical technology company, designs, develops, manufactures, markets, and sells products, therapies, and services. The company operates in two segments, Cardiopulmonary and Neuromodulation. The Cardiopulmonary segment provides cardiopulmonary products, including heart-lung machines, oxygenators, autotransfusion systems, perfusion tubing systems, cannula, and other related accessories, as well as services related products. The Neuromodulation segment offers VNS Therapy System, an implantable pulse generator and connective lead that stimulates the vagus nerve, surgical equipment to assist with the implant procedure, and equipment and instruction manuals; and devices that deliver neuromodulation therapy for treating drug-resistant epilepsy and depression. This segment also includes the development and clinical testing of aura6000 system for treating obstructive sleep apnea. It serves perfusionists, neurologists, neurosurgeons, hospitals, other healthcare professionals and medical institutions, and healthcare providers. The company sells its medical devices through direct sales representatives, agents, and independent distributors in the United States, the United Kingdom, Germany, France, Italy, the Netherlands, Spain, Belgium, Poland, Sweden, Switzerland, Austria, Norway, Portugal, Finland, Denmark, and internationally. LivaNova PLC was incorporated in 2015 and is headquartered in Gloucester, the United Kingdom.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United Kingdom
- Website
- livanova.com
News
Baird Maintains Outperform on LivaNova, Raises Price Target to $111 
LivaNova PLC (LIVN) Q3 2026 Earnings Call Transcript 
LivaNova Q3 Earnings Call Highlights 
Needham Maintains Buy on LivaNova, Raises Price Target to $112 
12 Health Care Stocks Moving In Wednesday's Intraday Session 
LivaNova (LIVN) Reports Q3 Earnings: What Key Metrics Have to Say 
Wayfair, Lendingtree, Bruker, Zimmer Biomet And Other Big Stocks Moving Higher On Wednesday 
LivaNova (LIVN) Surpasses Q3 Earnings and Revenue Estimates 
LivaNova Raises FY2026 Adj EPS Guidance from $4.30-$4.40 to $4.40-$4.50 vs $4.37 Est; Raises FY2026 Sales Guidance from $1.499B-$1.513B to $1.513B-$1.527B vs $1.522B Est - LivaNova Q3 Adj. EPS $1.23 Beats $1.06 Estimate, Sales $393.100M Beat $381.067M Estimate
Your note
Sign in to keep a note on LIVN — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 13.73% | 7,565,342 | 712.58M | Jun 29, 2026 |
| Primecap Management Company | 7.57% | 4,168,377 | 392.62M | Jun 29, 2026 |
| FMR, LLC | 5.71% | 3,147,068 | 296.42M | Jun 29, 2026 |
| Hood River Capital Management LLC | 4.66% | 2,565,477 | 241.64M | Jun 29, 2026 |
| AQR Capital Management, LLC | 4.28% | 2,356,191 | 221.93M | Jun 29, 2026 |
| Invesco Ltd. | 4.06% | 2,237,319 | 210.73M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Trust-iShares Core S&P Mid-Cap ETF | 3.56% | 1,963,642 | 184.96M | Sep 29, 2026 |
| VANGUARD HORIZON FUNDS-Vanguard Capital Opportunity Fund | 3.45% | 1,902,700 | 179.22M | Jun 29, 2026 |
| AIM Sector Funds (Invesco Sector Funds)-Invesco Small Cap Value Fund | 3.05% | 1,679,556 | 158.20M | Jul 30, 2026 |
| American Century ETF Trust-Avantis U.S. Small Cap Value ETF | 2.92% | 1,607,363 | 151.40M | Sep 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.63% | 1,450,682 | 136.64M | Sep 29, 2026 |
| Artisan Partners Funds Inc.-Artisan International Small-Mid Fund | 2.49% | 1,374,576 | 129.47M | Jun 29, 2026 |